Paragon 28 launches BEAST™ Cortical Fibers to expand its biological portfolio

ENGLEWOOD, Colo., November 14, 2023–(BUSINESS WIRE)–Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of its BEAST™ Cortical Fibers which provide an osteoinductive porous structure for cellular adhesion and osteoinductive potential to aid in cellular differentiation and bone formation. Designed to complement specific surgical applications in the foot and ankle, these loose cortical fibers are flexible with hydration, allowing application even to extremely challenging fusion sites. The cortical matrix absorbs bioactive fluid, including bone marrow aspirate, and supports cellular infiltration to stimulate efficient bone remodeling. Powerful processing capacity enables the retention of natural bone morphological proteins (BMPs) and other growth factors necessary to promote bone formation.

The addition of the BEAST™ Cortical Fibers strengthens Paragon 28’s biological product offering, including the PRESERVE™ Bone Wedge System, V92™ and V92™-FC+ Cellular Bone Matrices, MgNum™ Bone Void Filler, Paraderm™ Dermal Matrix, BEAST™ Demineralized Bone Matrices and Pro3™ Placenta and Umbilical Cord Regenerative Tissue Matrices. With this extensive portfolio, Paragon 28® offers its customers innovative biological solutions for reconstruction and trauma.

About Paragon 28, Inc.

Based in Englewood, CO., Paragon 28 is a leading medical device company focused exclusively on the foot and ankle orthopedic market and committed to improving the lives of patients. Since its inception, Paragon 28® has provided innovative orthopedic solutions, procedural approaches and devices covering a wide range of foot and ankle conditions, including fracture fixation, forefoot, ankle, progressive collapsing foot deformity (PCFD) or flat foot, Charcot foot and orthobiological agents . The company designs products with both the patient and surgeon in mind, with the goals of improving outcomes, reducing recurrences of disease and complications, and making procedures simpler, more consistent and reproducible.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to to: Paragon 28’s potential to shape a better future for foot and ankle patients. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates and assumptions, which speak only as of the date on which they are made, and are subject to risks and uncertainties, some of which we are not currently aware of. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at or at which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to these risks and uncertainties. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with Paragon 28’s business generally, see the current and future reports from Paragon 28 filed with the Securities and Exchange Commission. Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its Quarterly Reports on Form 10-Q, as updated periodically with its other filings with the SEC. These forward-looking statements are made as of the date of this press release, and Paragon 28 assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements . except as required by law.

Disclaimer

Nothing in this material is intended to provide specific medical advice or take the place of written law or regulation.

Contacts

Contact person for investors

Matthew Brinckman
Senior Vice President, Strategy and Investor Relations
Phone: (720) 912-1332
mbrinckman@paragon28.com